1. Home
  2. FUSE vs INAB Comparison

FUSE vs INAB Comparison

Compare FUSE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fusemachines Inc.

FUSE

Fusemachines Inc.

HOLD

Current Price

$0.28

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSE
INAB
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
11.8M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
FUSE
INAB
Price
$0.28
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
61.9K
★ 69.2K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 96.38
N/A
EPS
★ N/A
N/A
Revenue
★ $7,714,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.22
$0.72
52 Week High
$3.67
$2.73

Technical Indicators

Market Signals
Indicator
FUSE
INAB
Relative Strength Index (RSI) 35.08 32.88
Support Level $0.22 N/A
Resistance Level $0.41 $1.50
Average True Range (ATR) 0.05 0.08
MACD 0.00 -0.01
Stochastic Oscillator 21.73 9.62

Price Performance

Historical Comparison
FUSE
INAB

About FUSE Fusemachines Inc.

Fusemachines Inc is a provider of enterprise AI solutions, offering products such as AI Studio, AI Engines, and AI Agents, along with supporting services across various industries. Its solutions are supported by a talent pool from underserved communities, enabling scalable and high-quality AI delivery while promoting access to AI. The Company serves clients across industries, including healthcare, media, technology, and government, helping address challenges such as improving forecasting accuracy, reducing data entry errors, automating recruitment, and detecting fraud. Its product suite includes AI Studio, AI Engines, and AI Agents, designed to build, deploy, and scale AI solutions, and it operates in Nepal and the United States.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: